Jump to content

Abiomed

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Cydebot (talk | contribs) at 01:58, 28 October 2015 (Robot - Removing category Interlocking directorates per CFD at Wikipedia:Categories for discussion/Log/2015 October 20.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Abiomed Inc.
IndustryMedical Devices
Founded1981
HeadquartersDanvers, MA United States and Aachen, Germany
Key people
Michael R. Minogue, CEO, President & Chairman of the board
Mr. Robert L. Bowen, CFO
Dr. David Weber, COO
ProductsAbioCor
Impella
iPulse
IAB
AB5000
BVS 5000
RevenueIncrease US$73.2 Million (FY 2009)[1]
Decrease US$-29.5 Million (FY 2009)[1]
Decrease US$-31.6 Million (FY 2009)[1]
Total assetsIncrease US$136 Million (FY 2009)[2]
Total equityIncrease US$116 Million (FY 2009)[2]
Number of employees
500 (2013)
Websitewww.abiomed.com

Abiomed (NASDAQ: ABMD) is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. It is headquartered in Danvers, Massachusetts and has an additional office in Aachen, Germany. It has 500 employees. Michael R. Minogue joined Abiomed in 2004, and as CEO, Chairman and President. Minogue is a military veteran who served for four years on active duty in the U.S. Army and for eight years in the Army’s Individual Ready Reserve. Minogue served in Operation Desert Storm and earned multiple distinctions, including the Bronze Star. He is a 1989 graduate of the United States Military Academy at West Point. Minogue helped found the Medical Technology Veterans Program (MVP), a yearlong career training and mentorship initiative designed to help veterans entering the civilian workforce transition into jobs in the medical device and diagnostic industries.(*) He currently serves as chairman of the program.

Board of Directors

Abiomed Board of Directors include Michael R. Minogue, CEO, W. Gerald Austen, Harvard Medical School and the Massachusetts General Hospital, Louis E. Lataif, Boston University School of Management, Dorothy E. Puhy, Dana Farber Cancer Institute, Martin P. Sutter, Essex Woodlands Health Ventures, Henri A. Termeer, former-CEO Genzyme, Paul G. Thomas, CEO Roka Bioscience.[3]

References

  1. ^ a b c ABIOMED (ABMD) annual SEC income statement filing via Wikinvest
  2. ^ a b ABIOMED (ABMD) annual SEC balance sheet filing via Wikinvest
  3. ^ "BOD". Abiomed. nd. Retrieved 27 September 2015.